Physician profile
Kevin A Horvath
NPI 1033219365
$6,903.91
in general payments reported to CMS, 2019-2025
16 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 97% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $424 · 2021: $852 · 2022: $1,155 · 2023: $1,036 · 2024: $1,153 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654 · Education: $12.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.91 |
| Education | $12.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,429.53 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $1,184.00 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $857.86 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $634.89 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $545.58 | 2019-2022 | |
| Neos Therapeutics, Lp | $440.30 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $437.77 | 2024-2025 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $405.30 | 2020-2025 | Rexulti, Abilify Mycite |
| Collegium Pharmaceutical, INC. | $332.76 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $305.01 | 2019-2025 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.41 | 2025 | Caplyta |
| Rhodes Pharmaceuticals L.P. | $67.83 | 2019 | |
| Adlon Therapeutics L.P. | $42.35 | 2019-2020 | |
| Abbvie INC. | $23.98 | 2025 | |
| Alfasigma USA, INC. | $18.22 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Horvath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.